U.S. FDA grants Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis Roche, 17 Feb 2016 Accessed on 23 Feb 2016 from http://www.roche.com/investors/updates/inv-update-2016-02-17.htm. CommentRecommendBookmarkWatch
